COMP <GO>
ASST vs BRK-B // RETURN ON INVESTED CAPITAL (ROIC)
Strive Inc. (NASDAQ) VS. Berkshire Hathaway Inc. (NYSE) • 15-METRIC TALLY: ASST 6
— BRK-B 7
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ASST
LAST: $22.20 (-10.88%) • MKT CAP: $3.17B
roic
18.80%
LAST: $542.49 (+0.10%) • MKT CAP: $1.16T
roic
11.47%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ASST VS. BRK-B)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ASST | BRK-B | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 18.80% | 11.47% | +7.33 | ASST | /roic <GO> |
| EV/EBITDA & P/E Valuation | 19.7x | 9.7x | +10.02 | BRK-B | /valuation <GO> |
| Free Cash Flow Yield | 2.21% | 2.09% | +0.12 | ASST | /fcf-yield <GO> |
| Operating Margin | 13.90% | 27.80% | -13.90 | BRK-B | /operating-margins <GO> |
| Net Profit Margin | 10.90% | 22.30% | -11.40 | BRK-B | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 3.93% | +176.07 | ASST | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 2.85 | +23.15 | ASST | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 4/9 | +5.00 | ASST | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 3.55% | +2.95 | BRK-B | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.7 | 66.8 | -30.11 | BRK-B | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.89 | 0.61 | +0.28 | ASST | /macro-sensitivity <GO> |
| Forward P/E Multiple | 27.6x | 24.3x | +3.26 | BRK-B | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.17B | $1.16T | -$1.16T | BRK-B | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ASST REV | BRK-B REV | ASST GROSS % | BRK-B GROSS % | ASST FCF | BRK-B FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $371.44B | — | — | $0 | $25.04B |
| FY 2024 | $3.6M | $371.43B | 44.0% | — | -$21.6M | $11.62B |
| FY 2023 | $277.0K | $364.48B | 44.0% | — | -$3.8M | $29.79B |
| FY 2022 | — | $302.02B | — | — | — | $21.89B |
| FY 2021 | — | $276.19B | — | — | — | $26.15B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ASST // BETA 0.89
BRK-B // BETA 0.61